Fig. 2: Clinical outcomes in patients who had surgical resection and whose tumors did not have known EGFR or ALK alterations. | Nature Medicine

Fig. 2: Clinical outcomes in patients who had surgical resection and whose tumors did not have known EGFR or ALK alterations.

From: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Fig. 2: Clinical outcomes in patients who had surgical resection and whose tumors did not have known EGFR or ALK alterations.The alternative text for this image may have been generated using AI.

a, Pathological response (n = 143). Pathological regression is defined as percentage viable tumor cells – 100%. b, DFS by MPR status in patients with R0 resections (n = 137). c, OS by MPR status in patients with R0 resections (n = 137). HR, hazard ratio.

Back to article page